Drug Trial Radar · NCT00226499
Evaluate Vaccine Against Chickenpox and a Combined Vaccine Against 4 Viral Childhood Diseases: Measles, Mumps, Rubella and Chickenpox
Last checked: Nov 20, 2026Latest source record: Sep 23, 2019 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
5,803
Actual
Start
Sep 1, 2005
Primary completion
Oct 12, 2006
Study completion Oct 12, 2006
Sponsor
- Lead sponsor
- GlaxoSmithKlineGSK (GSK)
- Sponsor type
- Industry
- First posted
- Sep 27, 2005
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Prevention
- FDA-regulated drug
- No
- Who can join
- All sexes, from 11 months, up to 22 months
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
An observer-blind study to evaluate GlaxoSmithKline Biologicals' live attenuated varicella vaccine and GlaxoSmithKline Biologicals' combined measles-mumps-rubella-varicella vaccine in the prevention of varicella disease in children. The Protocol Posting has been updated in order to comply with the FDA Amendment Act, Sep 2007.
Conditions
- Varicella
- Chickenpox Vaccines
Interventions
Priorix-tetra™Biological
2 doses administered subcutaneously, one at Day 0 and the other at Day 42 to subjects in MMRV Group
Priorix™Biological
2 doses administered subcutaneously, one at Day 0 and the other at Day 42 to subjects in MMR Group and one dose administered subcutaneously at Day 0 to subjects in OKAH Group
Varilrix™Biological
1 dose administered subcutaneously at Day 42 to subjects in OKAH Group
Primary outcomes
What the sponsor says the trial is designed to measure.
- Phase A: Number of Subjects With Confirmed Varicella CaseTime frame: From 42 days post dose 2 until the end of Phase A
Locations
104 sites in 10 countries. Site status is shown where the registry gives one.
GSK Investigational Site
Brno, Czechia
GSK Investigational Site
Chomutov, Czechia
GSK Investigational Site
Děčín, Czechia
GSK Investigational Site
Havlíčkův Brod, Czechia
GSK Investigational Site
Hradec Králové, Czechia
GSK Investigational Site
Humpolec, Czechia
GSK Investigational Site
Jindřichův Hradec, Czechia
GSK Investigational Site
Kolín, Czechia
GSK Investigational Site
Liberec, Czechia
GSK Investigational Site
Moravská Ostrava, Czechia
GSK Investigational Site
Náchod, Czechia
GSK Investigational Site
Ostrava, Czechia
GSK Investigational Site
Pardubice, Czechia
GSK Investigational Site
Pilsen, Czechia
GSK Investigational Site
Prague, Czechia
GSK Investigational Site
Prague, Czechia
GSK Investigational Site
Prague, Czechia
GSK Investigational Site
Prague, Czechia
GSK Investigational Site
Prague, Czechia
GSK Investigational Site
Znojmo, Czechia
GSK Investigational Site
Arta, Greece
GSK Investigational Site
Athens, Greece
GSK Investigational Site
Athens, Greece
GSK Investigational Site
Athens, Greece
GSK Investigational Site
Giannitsá, Greece
GSK Investigational Site
Karditsa, Greece
GSK Investigational Site
Komotini, Greece
GSK Investigational Site
Ptolemaida, Greece
GSK Investigational Site
Thessaloniki, Greece
GSK Investigational Site
Tripoli, Greece
GSK Investigational Site
Véria, Greece
GSK Investigational Site
Quarto (NA), Campania, Italy
GSK Investigational Site
Ferrara, Emilia-Romagna, Italy
GSK Investigational Site
Udine, Friuli Venezia Giulia, Italy
GSK Investigational Site
Genoa, Liguria, Italy
GSK Investigational Site
Milan, Lombardy, Italy
GSK Investigational Site
Novara, Piedmont, Italy
GSK Investigational Site
Alghero (SS), Sardinia, Italy
GSK Investigational Site
Ozieri (SS), Sardinia, Italy
GSK Investigational Site
Florence, Tuscany, Italy
Showing 40 of 104 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.